已收盘 04-02 16:00:00 美东时间
-0.080
-0.69%
今日重点评级关注:Evercore ISI集团:维持Caribou Biosciences"跑赢大市"评级,目标价从11美元升至13美元;富国银行:上调uniQure评级至"超配",目标价从15美元升至60美元
03-10 15:05
Stifel analyst Thomas Stephan maintains Orthofix Medical (NASDAQ:OFIX) with a Buy and lowers the price target from $22 to $18.
03-09 20:37
今日重点评级关注:HC Wainwright & Co.:维持NovoCure"买入"评级,目标价从47美元升至49美元;Citizens:维持Ironwood医药"跑赢大市"评级,目标价从8美元升至10美元
02-27 11:07
Canaccord Genuity analyst Caitlin Burrows maintains Orthofix Medical (NASDAQ:OFIX) with a Buy and lowers the price target from $24 to $20.
02-27 04:02
Earnings Call Insights: Orthofix Medical Inc. (OFIX) Q4 2025 Management View Massimo Calafiore, President and CEO, reported "strong consistent performance in Bone Growth Therapies and U.S. Limb Recons...
02-25 01:08
Orthofix Q4 sales slightly beat expectations, EBITDA beats Overview Medical technology firm's Q4 net sales slightly beat analyst expectations Adjusted EBITDA for Q4 beat analyst estimates Company reported strong free cash flow generation in Q4 Outlook Orthofix expects 2026 net sales between $850 mln
02-24 20:12
The earnings results for Orthofix Medical (NASDAQ:OFIX) for Q4 were made public...
02-24 20:06
Orthofix Medical (NASDAQ:OFIX) sees FY2026 sales of $850.000 million-$860.000 million vs $862.758 million analyst estimate.
02-24 20:04
Orthofix Medical (NASDAQ:OFIX) reported quarterly earnings of $0.24 per share which beat the analyst consensus estimate of $0.12 by 100 percent. This is a 1100 percent increase over earnings of $0.02 per share from the
02-24 20:04
Orthofix posts Q4 2025 net loss of USD 2.2 million and free cash flow of USD 16.8 million (+16.8x) Orthofix reported Q4 2025 net sales of USD 219.9 million (+2.0%), or USD 218.6 million on a non-GAAP pro forma basis excluding M6 disc sales. Q4 2025 net loss was USD 2.2 million, while non-GAAP pro fo
02-24 20:01